Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, S.
Right arrow Articles by Topley, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, S.
Right arrow Articles by Topley, N.
J Am Soc Nephrol 13:S97-S103, 2002
© 2002 American Society of Nephrology


Peritoneal Dialysis

Continuous Dialysis with Bicarbonate/Lactate-Buffered Peritoneal Dialysis Fluids Results in a Long-Term Improvement in Ex Vivo Peritoneal Macrophage Function

Suzanne Jones*, Clifford J. Holmes{dagger}, Ruth K. Mackenzie*, Rachel Stead*, Gerald A. Coles*, John D. Williams*, Dirk Faict{ddagger} and Nicholas Topley*

*Institute of Nephrology, University of Wales College of Medicine, Cardiff, Wales, United Kingdom; and Baxter Healthcare Renal Division, {dagger}Nivelles, Belgium, and {ddagger}McGaw Park, Illinois.

Correspondence to Dr. Clifford Holmes, 1620 Waukegan Road, McGaw Park, IL 60085. Phone: 847-473-6352; Fax: 847-473-6902; E-mail: holmesc{at}baxter.com

Abstract

ABSTRACT. To circumvent the potentially negative consequences of long-term exposure to unphysiologic acidic lactate-buffered peritoneal dialysis fluids (PDF), neutral pH solutions buffered with bicarbonate/lactate have recently been introduced in phase 2 and 3 clinical trials. This study examines the longitudinal changes in peritoneal macrophage (PMØ) function in patients dialyzed continuously with either lactate (LPD; 40 mM lactate, pH 5.2)-buffered or bicarbonate/lactate (TBL; 25 mM/15 mM bicarbonate/lactate, pH 7.3)-buffered PDF. Before the study, during the run in period of a phase 3 clinical trial, all patients had been taking LPD for at least the previous 18 wk. At the beginning of the study (day 0), both constitutive and serum-treated zymosan (STZ) stimulated tumor necrosis factor alpha (TNF-{alpha}) synthesis were assessed in PMØ isolated from 12-h dwell effluent (with 1.36% glucose) in all patients. The patients were subsequently randomized to either continuous TBL or LPD therapy and PMØ function was assessed after further 3- and 6-mo periods in all patients. At all time points measured STZ induced a dose-dependent increase in PMØ TNF-{alpha} secretion (P = 0.043 versus control for doses greater than 100 µg/ml). In patients continuously dialyzed with LPD, constitutive PMØ TNF-{alpha} synthesis levels (mean ± SEM, pg/106 PMØ per18 h, n = 5 patients) were 154 ± 65, 261 ± 60, and 101 ± 99 at 0, 3, and 6 mo, respectively. Stimulated STZ (1000 µg/ml) levels were 1340 ± 519, 1046 ± 586, and 758 ± 250 at 0, 3, and 6 mo, respectively. In patients dialyzed with TBL, constitutive PMØ TNF-{alpha} synthesis levels (pg/106 PMØ per 18 h, n = 5 patients) were 300 ± 136, 106 ± 35, and 213 ± 62 at 0, 3, and 6 mo, respectively. Stimulated STZ (1000 µg/ml) levels were 1969 ± 751, 1541 ± 330, and 2670 ± 671 at 0, 3, and 6 mo, respectively. At 6 mo, STZ-stimulated PMØ TNF-{alpha} synthesis was significantly higher in patients treated with TBL compared with those treated with LPD (P = 0.0035). These data suggest that in patients continuously dialyzed with a neutral pH solution, there is a long-term improvement in PMØ function compared with patients on conventional therapy. Better PMØ function suggests improved host defense status and may affect the peritoneum’s susceptibility to infection and potentially reduce the negative consequences of repeated intraperitoneal inflammation on long-term membrane function.




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
E. A. Brown
Peritonitis: limiting the damage
Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1539 - 1541.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
P. J. Margetts and D. N. Churchill
Acquired Ultrafiltration Dysfunction in Peritoneal Dialysis Patients
J. Am. Soc. Nephrol., November 1, 2002; 13(11): 2787 - 2794.
[Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP